Investigating the role of CHCHD2 gene dysfunction in Lewy body diseases
Official title: Pathological signatures and pathways of CHCHD2 dysfunction in Lewy body diseases
Funded at Louis Stokes Cleveland VA Medical Center · NIH-10922177 · Data updated 2026-11-12
This study is looking at how changes in the CHCHD2 gene, which is connected to familial Parkinson's disease, affect brain health in mice, with the hope of finding ways to improve symptoms by fixing these gene changes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Louis Stokes Cleveland VA Medical Center NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | October 1, 2024 |
| Project end | September 30, 2028 |
| Funding year | 2025 |
| NIH project number | 1I01BX006539-01 |
| Project ID | NIH-10922177 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with familial Parkinson's disease or Lewy body diseases, particularly those with known CHCHD2 mutations.
✕Less likely to help
Patients with Lewy body diseases who do not have a genetic link to CHCHD2 or those with other unrelated neurodegenerative conditions may not benefit from this research.
What this research studies
This research focuses on understanding how mutations in the CHCHD2 gene, which is linked to familial Parkinson's disease and other Lewy body diseases, affect brain health. The study uses transgenic mice to explore the impact of CHCHD2 mutations on mitochondrial function and the clearance of misfolded proteins. By examining these mechanisms, researchers aim to identify the pathological changes associated with CHCHD2 dysfunction and how restoring normal CHCHD2 levels may alleviate disease symptoms.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating Lewy body diseases and improving patient outcomes.
How similar studies have gone: While the specific approach of targeting CHCHD2 dysfunction is relatively novel, previous research has shown promise in understanding the role of mitochondrial dysfunction in neurodegenerative diseases.
Where this research is happening
-
Louis Stokes Cleveland VA Medical Center
Cleveland, United States Active
Researchers
- Principal investigator: Kang, David E — Louis Stokes Cleveland VA Medical Center
- Study coordinator: Kang, David E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.